Catalogue Number: A8458-APE
Manufacturer: | Apexbio |
Molecular Formula: | C8H11N3O3S |
Physical state: | A solid |
Type: | Enzyme Inhibitors |
Shipping Condition: | Blue Ice |
Unit(s): | 10 mg, 10 mM (in 1mL DMSO), 50 mg |
Description: Lamivudine, a nucleoside analog, is a potent reverse transcriptase inhibitor, with IC50 value of 0.316 µM against human immunodeficiency virus type 1 (HIV-1) [1]. Reverse transcriptase is a RNA-dependent DNA polymerase, playing a critical role in retroviral replication. Thus, reverse transcriptase has been made a target of antiretroviral chemotherapy [1]. Lamivudine was most potent against simian retrovirus types 1 and 2 (SRV-1, SRV-2), and HIV-1, with IC50 values of 10, 0.316 and 0.316 µM, respectively, but did not inhibit foamy viruses and amphotrophic murine leukaemia virus (MLV-A) [1]. In human coinfected with HIV-1 and hepatitis B virus (HBV), Lamivudine (150 mg, b.i.d., p.o.) displayed dual efficacy through both delayed HIV-1 disease progression and a favorable biochemical and HBV virologic response. Twelve months of Lamivudine therapy led to HBV DNA and hepatitis B e antigen (HBeAg) losses of ~40% and ~20%, respectively, and more alanine aminotransferase (ALT) normalization than that in the placebo group [2]. References:[1]. Rosenblum L L, Patton G, Grigg A R, et al. Differential susceptibility of retroviruses to nucleoside analogues. Antiviral Chemistry and Chemotherapy, 2001, 12(2): 91-97.[2]. Dore G J, Cooper D A, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. The Journal of Infectious Diseases, 1999, 180(3): 607-613.
Store at -20°C
Nucleoside analog reverse transcriptase inhibitor
C1C(OC(S1)CO)N2C=CC(=NC2=O)N
≥10.5 mg/mL in DMSO; ≥11.4 mg/mL in EtOH with ultrasonic; ≥89.4 mg/mL in H2O with ultrasonic